The efficacy of azathioprine in relapsing-remitting multiple sclerosis
- PMID: 1985289
- DOI: 10.1212/wnl.41.1.20
The efficacy of azathioprine in relapsing-remitting multiple sclerosis
Abstract
We randomized 59 patients with relapsing-remitting multiple sclerosis to receive azathioprine (AZA) 3.0 mg/kg daily or placebo in a double-masked therapeutic trial. Analysis of data for predetermined primary outcome measures demonstrated a significant difference favoring AZA for observed mean exacerbation rate after 2 years of therapy and time to deterioration in both Ambulation Index and Kurtzke Expanded Disability Status Scale score. This study confirms a modest therapeutic benefit for azathioprine previously reported by other investigators.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical